Data from Functional Analysis Identifies Damaging <i>CHEK2</i> Missense Variants Associated with Increased Cancer Risk
CHEK2
Loss function
DOI:
10.1158/0008-5472.c.6513927.v1
Publication Date:
2023-03-31T21:17:37Z
AUTHORS (16)
ABSTRACT
<div>Abstract<p>Heterozygous carriers of germline loss-of-function variants in the tumor suppressor gene checkpoint kinase 2 (<i>CHEK2)</i> are at an increased risk for developing breast and other cancers. While truncating <i>CHEK2</i> known to be pathogenic, interpretation missense uncertain significance (VUS) is challenging. Consequently, many VUS remain unclassified both functionally clinically. Here we describe a mouse embryonic stem (mES) cell–based system quantitatively determine functional impact 50 human <i>CHEK2</i>. By assessing activity CHK2 phosphorylate one its main targets, Kap1, <i>Chek2</i> knockout mES cells, 31 were found impair protein function similar extent as variants, while 9 resulted intermediate defects. Mechanistically, most impaired by causing instability or impairing activation through (auto)phosphorylation. Quantitative results showed that degree dysfunction correlates with cancer. Both damaging group [OR 2.23; 95% confidence interval (CI), 1.62–3.07; <i>P</i> < 0.0001] (OR 1.63; CI, 1.21–2.20; = 0.0014) associated cancer risk, did not show this association 1.13; 0.87–1.46; 0.378). Finally, <i>CHEK2</i>, c.486A>G/p.D162G, was also identified, which cosegregated familial prostate Altogether, these assays efficiently reliably identified associate cancer.</p>Significance:<p>Quantitative assessment consequences identifies may aid clinical management patients carriers.</p></div>
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (0)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....